Albatroz's unique proprietary technology aims to control extracellular matrix (ECM) remodeling in disease, with our initial focus on solid tumors and arthritis. ​Our novel ECM degradation target is a protein complex activated by a glycosylation pathway critically involved in the pathogenesis of these diseases.

CANCER: SOLID TUMORS

ARTHRITIS

The ECM is a physical barrier preventing the growth of solid tumors in most organs of the body. Tumors need to destroy this barrier to create space for their growth and proliferation to other organs in the body.
​
​We have developed unique therapeutic antibodies that block a tumor surface protein that is critical to the tumor's ability to degrade the ECM. Our antibodies thus block ECM destruction, stop tumor growth and help prevent tumor metastasis to other organs.

Destruction of the cartilage ECM is characteristic of many forms of arthritis, including osteoarthritis and rheumatoid arthritis. 
​
We are developing therapeutics antibodies that block the destruction of cartilage in the joints, thereby preventing the progression of arthritis and allowing the joint to heal.